[go: up one dir, main page]

MX2009001231A - Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido. - Google Patents

Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido.

Info

Publication number
MX2009001231A
MX2009001231A MX2009001231A MX2009001231A MX2009001231A MX 2009001231 A MX2009001231 A MX 2009001231A MX 2009001231 A MX2009001231 A MX 2009001231A MX 2009001231 A MX2009001231 A MX 2009001231A MX 2009001231 A MX2009001231 A MX 2009001231A
Authority
MX
Mexico
Prior art keywords
time
extended period
active principle
subcutaneous implants
principle over
Prior art date
Application number
MX2009001231A
Other languages
English (en)
Inventor
Patrice Mauriac
Pierre Marion
Original Assignee
Mediolanum Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Pharmaceuticals Ltd filed Critical Mediolanum Pharmaceuticals Ltd
Publication of MX2009001231A publication Critical patent/MX2009001231A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los implantes subcutáneos obtenidos por extrusión que contiene un ingrediente activo, y un excipiente hidrofílico dispersado en una matriz PLGA de manera que el rango de peso: (Ingrediente Activo (AI)+ Excipiente(E)/PLGA es mayor que 0.05 y menor a 1.
MX2009001231A 2006-08-02 2007-08-01 Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido. MX2009001231A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001539A ITMI20061539A1 (it) 2006-08-02 2006-08-02 Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
PCT/EP2007/057961 WO2008015232A1 (en) 2006-08-02 2007-08-01 Subcutaneous implants releasing an active principle over an extended period of time

Publications (1)

Publication Number Publication Date
MX2009001231A true MX2009001231A (es) 2009-04-28

Family

ID=37765841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001231A MX2009001231A (es) 2006-08-02 2007-08-01 Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido.

Country Status (15)

Country Link
US (1) US20090246245A1 (es)
EP (1) EP2054028B9 (es)
JP (1) JP2009545351A (es)
KR (1) KR20090046837A (es)
CN (1) CN101522169B (es)
AU (1) AU2007280391A1 (es)
BR (1) BRPI0714818A2 (es)
CA (1) CA2658592A1 (es)
EA (1) EA017473B1 (es)
ES (1) ES2389981T3 (es)
IT (1) ITMI20061539A1 (es)
MX (1) MX2009001231A (es)
PL (1) PL2054028T3 (es)
PT (1) PT2054028E (es)
WO (1) WO2008015232A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10753023B2 (en) 2010-08-13 2020-08-25 Kimberly-Clark Worldwide, Inc. Toughened polylactic acid fibers
US8936740B2 (en) 2010-08-13 2015-01-20 Kimberly-Clark Worldwide, Inc. Modified polylactic acid fibers
WO2012088306A2 (en) * 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
CN117442742A (zh) * 2015-06-18 2024-01-26 灵敏生物公司 可植入的药物递送组合物及其使用方法
JP2021529747A (ja) * 2018-06-25 2021-11-04 タイタン ファーマシューティカルズ インコーポレイテッド 親油性又は両親媒性医薬物質の放出のためのインプラント

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
DE60237449D1 (de) * 2001-06-22 2010-10-07 Univ Johns Hopkins Med Ammensetzungen und damit in beziehung stehende verwendungen
ITMI20031302A1 (it) * 2003-06-26 2004-12-27 Mediolanum Pharmaceuticals Ltd Uso di etanolo come plasticizzante per preparare impianti sottocutanei contenenti principi attivi termolabili dispersi in una matrice di plga.
CA2530120A1 (en) * 2003-06-26 2005-01-06 Mediolanum Pharmaceuticals Ltd. Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component

Also Published As

Publication number Publication date
AU2007280391A1 (en) 2008-02-07
CA2658592A1 (en) 2008-02-07
JP2009545351A (ja) 2009-12-24
EP2054028B9 (en) 2012-09-26
WO2008015232A8 (en) 2008-05-22
EA200901148A1 (ru) 2010-02-26
EA017473B1 (ru) 2012-12-28
BRPI0714818A2 (pt) 2013-05-21
PT2054028E (pt) 2012-10-10
US20090246245A1 (en) 2009-10-01
KR20090046837A (ko) 2009-05-11
CN101522169A (zh) 2009-09-02
ES2389981T3 (es) 2012-11-05
WO2008015232A1 (en) 2008-02-07
HK1131546A1 (en) 2010-01-29
EP2054028B1 (en) 2012-06-27
EP2054028A1 (en) 2009-05-06
CN101522169B (zh) 2013-02-20
ITMI20061539A1 (it) 2008-02-03
PL2054028T3 (pl) 2013-02-28

Similar Documents

Publication Publication Date Title
EA200900246A1 (ru) Подкожные имплантаты, высвобождающие активный компонент в течение продолжительного периода времени
MX2009001231A (es) Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido.
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
EP2636416A3 (en) Phase-separated block copolymer coatings for implantable medical devices
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
GB2430157A (en) Personal care products and methods for inhibiting the adherence of flora to skin
UY32503A (es) Formulación pesticida de uso agrícola a base de avermectina y un agente fotoprotector
BG108870A (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
MX362908B (es) Implantes que contienen fármacos y métodos de uso de los mismos.
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
TW200635616A (en) Organic compounds
RU2007122391A (ru) S-миртазапин для лечения приливов
TW200509980A (en) Parasiticidal composition
GR1005244B (el) Συνθεση ρυθμισης αναπτυξης εντομου
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
MX2009001232A (es) Implantes subcutaneos que liberan un principio activo en un periodo de tiempo extendido.
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
GEP20094589B (en) Orally dispersible pharmaceutical composition and process for the preparation thereof
TW200640472A (en) Solid pharmaceutical composition comprising telithromycin
ATE545410T1 (de) Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
IL149899A0 (en) MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HCl AS ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
FG Grant or registration